FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943615801> ?p ?o ?g. }

• W2943615801 abstract "Few patients with pancreatic cancer may be candidates for immediate surgical resection at the initial diagnosis. Even if patients with borderline resectable pancreatic cancer (BRPC), micrometastases may occur before surgery. Therefore, neoadjuvant therapy is vital for improved survival, which has been confirmed in previous studies that neoadjuvant chemotherapy with or without radiotherapy provides superior overall compared with upfront surgery. However, question of whether the addition of radiotherapy to neoadjuvant chemotherapy can improve prognosis compared with chemotherapy alone is a challenging matter. Moreover, most of previous studies only adopted conventional radiotherapy as the neoadjuvant modality though stereotactic body radiation therapy (SBRT) has been proven effective and commonly employed in pancreatic cancer. Also, no studies have evaluated the efficacy of S-1 as the neoadjuvant chemotherapy regimen for BRPC albeit similar prognosis has been found between S-1 and gemcitabine in advanced pancreatic cancer. Hence, the aim of this study is to investigate whether neoadjuvant chemotherapy plus SBRT results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with SBRT and S-1 plus nab-paclitaxel with SBRT. Patients with biopsy and radiographically confirmed BRPC, no prior treatment and severe morbidities are enrolled. They will be randomly allocated into three groups: neoadjuvant gemcitabine plus nab-paclitaxel, neoadjuvant gemcitabine plus nab-paclitaxel with SBRT and neoadjuvant S-1 plus nab-paclitaxel with SBRT. Standard doses of gemcitabine and nab-paclitaxel are used. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT. Artery first approach pancreaticoduodenectomy or radical antegrade modular pancreatosplenectomy will be used for the tumor in the head or body and tail of the pancreas, respectively. The primary endpoint is overall survival. The secondary outcomes are disease free survival, pathological complete response rate, R0 resection rate and incidence of adverse effects. If results show the survival benefits of neoadjuvant chemotherapy plus SBRT and similar outcomes between S-1 and gemcitabine, it may provide evidence of clinical practice of this modality for BRPC. The study has been registered in ClinicalTrial.gov ( NCT03777462 )." @default.
• W2943615801 created "2019-05-09" @default.
• W2943615801 creator A5002039083 @default.
• W2943615801 creator A5009902978 @default.
• W2943615801 creator A5031808825 @default.
• W2943615801 creator A5037290417 @default.
• W2943615801 creator A5039287818 @default.
• W2943615801 creator A5040987305 @default.
• W2943615801 creator A5044113923 @default.
• W2943615801 creator A5055712059 @default.
• W2943615801 creator A5070134243 @default.
• W2943615801 creator A5073844760 @default.
• W2943615801 date "2019-03-27" @default.
• W2943615801 modified "2023-10-14" @default.
• W2943615801 title "Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)" @default.
• W2943615801 cites W1964409752 @default.
• W2943615801 cites W1971005338 @default.
• W2943615801 cites W1994177577 @default.
• W2943615801 cites W2013436703 @default.
• W2943615801 cites W2027181541 @default.
• W2943615801 cites W2136706275 @default.
• W2943615801 cites W2143953275 @default.
• W2943615801 cites W2165480504 @default.
• W2943615801 cites W2170462613 @default.
• W2943615801 cites W2272984102 @default.
• W2943615801 cites W2514008771 @default.
• W2943615801 cites W2551390038 @default.
• W2943615801 cites W2621623711 @default.
• W2943615801 cites W2770835903 @default.
• W2943615801 cites W2781525129 @default.
• W2943615801 cites W2799575632 @default.
• W2943615801 cites W2801077576 @default.
• W2943615801 cites W2804068357 @default.
• W2943615801 cites W2804844375 @default.
• W2943615801 cites W2889646458 @default.
• W2943615801 cites W2889748477 @default.
• W2943615801 cites W2896970133 @default.
• W2943615801 cites W2900425230 @default.
• W2943615801 cites W2912196744 @default.
• W2943615801 doi "https://doi.org/10.1186/s13014-019-1254-8" @default.
• W2943615801 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6437889" @default.
• W2943615801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30917842" @default.
• W2943615801 hasPublicationYear "2019" @default.
• W2943615801 type Work @default.
• W2943615801 sameAs 2943615801 @default.
• W2943615801 citedByCount "15" @default.
• W2943615801 countsByYear W29436158012020 @default.
• W2943615801 countsByYear W29436158012021 @default.
• W2943615801 countsByYear W29436158012022 @default.
• W2943615801 countsByYear W29436158012023 @default.
• W2943615801 crossrefType "journal-article" @default.
• W2943615801 hasAuthorship W2943615801A5002039083 @default.
• W2943615801 hasAuthorship W2943615801A5009902978 @default.
• W2943615801 hasAuthorship W2943615801A5031808825 @default.
• W2943615801 hasAuthorship W2943615801A5037290417 @default.
• W2943615801 hasAuthorship W2943615801A5039287818 @default.
• W2943615801 hasAuthorship W2943615801A5040987305 @default.
• W2943615801 hasAuthorship W2943615801A5044113923 @default.
• W2943615801 hasAuthorship W2943615801A5055712059 @default.
• W2943615801 hasAuthorship W2943615801A5070134243 @default.
• W2943615801 hasAuthorship W2943615801A5073844760 @default.
• W2943615801 hasBestOaLocation W29436158011 @default.
• W2943615801 hasConcept C121608353 @default.
• W2943615801 hasConcept C126322002 @default.
• W2943615801 hasConcept C126838900 @default.
• W2943615801 hasConcept C143998085 @default.
• W2943615801 hasConcept C2776694085 @default.
• W2943615801 hasConcept C2777292972 @default.
• W2943615801 hasConcept C2778292576 @default.
• W2943615801 hasConcept C2780210213 @default.
• W2943615801 hasConcept C2780258809 @default.
• W2943615801 hasConcept C2781413609 @default.
• W2943615801 hasConcept C509974204 @default.
• W2943615801 hasConcept C530470458 @default.
• W2943615801 hasConcept C71924100 @default.
• W2943615801 hasConceptScore W2943615801C121608353 @default.
• W2943615801 hasConceptScore W2943615801C126322002 @default.
• W2943615801 hasConceptScore W2943615801C126838900 @default.
• W2943615801 hasConceptScore W2943615801C143998085 @default.
• W2943615801 hasConceptScore W2943615801C2776694085 @default.
• W2943615801 hasConceptScore W2943615801C2777292972 @default.
• W2943615801 hasConceptScore W2943615801C2778292576 @default.
• W2943615801 hasConceptScore W2943615801C2780210213 @default.
• W2943615801 hasConceptScore W2943615801C2780258809 @default.
• W2943615801 hasConceptScore W2943615801C2781413609 @default.
• W2943615801 hasConceptScore W2943615801C509974204 @default.
• W2943615801 hasConceptScore W2943615801C530470458 @default.
• W2943615801 hasConceptScore W2943615801C71924100 @default.
• W2943615801 hasIssue "1" @default.
• W2943615801 hasLocation W29436158011 @default.
• W2943615801 hasLocation W29436158012 @default.
• W2943615801 hasLocation W29436158013 @default.
• W2943615801 hasLocation W29436158014 @default.
• W2943615801 hasOpenAccess W2943615801 @default.
• W2943615801 hasPrimaryLocation W29436158011 @default.
• W2943615801 hasRelatedWork W1255356622 @default.
• W2943615801 hasRelatedWork W2100029565 @default.
• W2943615801 hasRelatedWork W2358701816 @default.
• W2943615801 hasRelatedWork W2367105124 @default.
• W2943615801 hasRelatedWork W2388481412 @default.

• next